In the News

Find articles and press on AgeneBio and research updates regarding hippocampal overactivity and aMCI.

September 16, 2015

JHU team gets $7.5 million to test Alzheimer’s drug

The Daily Record

A grant from the National Institutes of Health will allow researchers from the Johns Hopkins University to test a drug they hope will slow or prevent the onset of Alzheimer’s.

September 15, 2015

AgeneBio’s HOPE4MCI Phase 3 trial receives support from NIH

News Medical Net

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH).

September 15, 2015

Baltimore biopharm gets NIH grant

The Daily Record

AgeneBio, a Baltimore-based biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

July 16, 2015

Epilepsy Drug to Treat Alzheimer’s Disease Progression

HCP Live

Elderly patients with risk for dementia and Alzheimer’s disease may be able to utilize a novel therapeutic approach from an existing drug to reverse symptoms, according to research published in NeuroImage: Clinical.